JP Morgan Chase’s Scribe Therapeutics SCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding SCTX
BBA
JP Morgan Chase's SCTX Position: Q3 2026 in Review
JP Morgan Chase opened a new position in Scribe Therapeutics (SCTX) in Q3 2026: 6,028 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #5995 among its holdings.
63 funds tracked by Wall St. Rank hold SCTX as of Q3 2026.
- JP Morgan Chase held 6,028 shares of Scribe Therapeutics worth $139K as of Q3 2026.
- Scribe Therapeutics was a new JP Morgan Chase position in Q3 2026.
- Scribe Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5995 holding.
- 63 funds tracked by Wall St. Rank held Scribe Therapeutics as of Q3 2026.
Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.